; Hyperoxaluria – Pipeline Review, H1 2012
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Hyperoxaluria – Pipeline Review, H1 2012

VIEWS: 4 PAGES: 34

Hyperoxaluria - Pipeline Review, H1 2012, provides an overview of the Hyperoxaluria therapeutic pipeline. This report provides information on the therapeutic development for Hyperoxaluria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperoxaluria. 'Hyperoxaluria - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
  • pg 1
									                      Hyperoxaluria – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1824IDB
                                                                                             Publication Date: March 2012




Hyperoxaluria – Pipeline Review, H1 2012                                                    GMDHC1824IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Hyperoxaluria – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Hyperoxaluria Overview ..................................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Hyperoxaluria ..................................................................................................................... 7
Hyperoxaluria Therapeutics under Development by Companies........................................................................................................ 9
Hyperoxaluria Therapeutics under Investigation by Universities/Institutes ....................................................................................... 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Pre-Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Hyperoxaluria Therapeutics – Products under Development by Companies.................................................................................... 14
Hyperoxaluria Therapeutics – Products under Investigation by Universities/Institutes ..................................................................... 15
Companies Involved in Hyperoxaluria Therapeutics Development .................................................................................................. 16
    OxThera AB ................................................................................................................................................................................. 16
    ReGenX Biosciences, LLC .......................................................................................................................................................... 17
    Amsterdam Molecular Therapeutics BV ...................................................................................................................................... 18
Hyperoxaluria – Therapeutics Assessment ...................................................................................................................................... 19
    Assessment by Monotherapy Products ....................................................................................................................................... 19
    Assessment by Route of Administration ...................................................................................................................................... 20
    Assessment by Molecule Type .................................................................................................................................................... 22
Drug Profiles..................................................................................................................................................................................... 24
    AMT-030 - Drug Profile ................................................................................................................................................................ 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
    Cystadane - Drug Profile ............................................................................................................................................................. 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    Oxabact - Drug Profile ................................................................................................................................................................. 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    AAV8 - Drug Profile ..................................................................................................................................................................... 28
         Product Description..........................................................................................................................................................
								
To top